IGM Biosciences Announces Third Quarter 2024 Financial Results …
6 days ago · In This Article: IGMS. – Imvotamab (CD20 x CD3) trials in rheumatoid arthritis, systemic lupus erythematosus and myositis ongoing; initial clinical data expected by mid-2025 –. – IGM-2644 ...
IGM Biosciences Announces Third Quarter 2024 Financial Results …
About IGM Biosciences, Inc. IGM Biosciences is a clinical-stage biotechnology company committed to developing and delivering a new class of medicines to treat patients with autoimmune and ...
IGM Biosciences Announces Third Quarter 2024 Financial Results …
6 days ago · About IGM Biosciences, Inc. IGM Biosciences is a clinical-stage biotechnology company committed to developing and delivering a new class of medicines to treat patients with autoimmune and ...
IGM Biosciences Announces Third Quarter 2024 Financial Results …
Sep 30, 2024 · IGM Biosciences is a clinical-stage biotechnology company committed to developing and delivering a new class of medicines to treat patients with autoimmune and inflammatory diseases. IGM’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only 2 ...
News - IGM Biosciences
Aug 14, 2024 · News. MOUNTAIN VIEW, Calif. , Nov. 04, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that management will present at three upcoming investor conferences: Guggenheim Healthcare. – …
IGM Biosciences' New Found Focus: Pivots From Cancer To …
Oct 1, 2024 · On Tuesday, IGM Biosciences Inc. (NASDAQ:IGMS) announced a strategic pivot and pipeline transformation to accelerate and deepen its leadership in developing T cell-engaging IgM antibodies for...
IGM Biosciences Announces Strategic Pivot to Focus Exclusively …
Sep 30, 2024 · IGMS. – Company to prioritize its pipeline of T cell engagers in autoimmune diseases, including ongoing clinical development of imvotamab in rheumatoid arthritis and systemic lupus erythematosus...
IGM Biosciences Announces FDA Clearance to Begin Clinical …
May 31, 2023 · IGM Biosciences Announces FDA Clearance to Begin Clinical Studies of Imvotamab in Lupus and Rheumatoid Arthritis. May 31, 2023 at 7:00 AM EDT. PDF Version. Imvotamab, a CD20 x CD3 bispecific monoclonal antibody, offers potential for deeper B cell depletion than currently approved therapies.
IGM Biosciences Shifts Focus to Autoimmunity - Nasdaq
5 days ago · IGM Biosciences, a clinical-stage biotechnology company, focuses on developing engineered IgM antibodies to treat autoimmune and inflammatory diseases. The recent third quarter 2024 earnings ...
Igm Biosciences: Navigating Financial Challenges Amidst Early …
5 days ago · Igm Biosciences has disclosed a new risk, in the Share Price & Shareholder Rights category.Igm Biosciences faces significant risks that could adversely impact its business and financial prospects ...
- Some results have been removed